 Kimi Kondo
Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiology | 4 | 2017 | 180 | 0.640 |
Why?
| | Lymphocele | 1 | 2013 | 2 | 0.420 |
Why?
| | Curriculum | 4 | 2018 | 992 | 0.380 |
Why?
| | Surgery, Computer-Assisted | 1 | 2013 | 101 | 0.370 |
Why?
| | Faculty | 1 | 2013 | 147 | 0.370 |
Why?
| | Kidney Neoplasms | 4 | 2016 | 403 | 0.270 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 570 | 0.270 |
Why?
| | Kidney Transplantation | 1 | 2013 | 708 | 0.260 |
Why?
| | Clinical Competence | 1 | 2013 | 1118 | 0.230 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1171 | 0.230 |
Why?
| | Ultrasonography, Interventional | 2 | 2016 | 141 | 0.220 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2016 | 44 | 0.220 |
Why?
| | Angiomyolipoma | 2 | 2016 | 24 | 0.220 |
Why?
| | Internship and Residency | 1 | 2013 | 1147 | 0.200 |
Why?
| | Diagnostic Imaging | 2 | 2016 | 332 | 0.190 |
Why?
| | Students, Medical | 2 | 2017 | 348 | 0.170 |
Why?
| | Education, Medical, Undergraduate | 2 | 2018 | 188 | 0.150 |
Why?
| | Radiology, Interventional | 1 | 2018 | 33 | 0.150 |
Why?
| | Schools, Medical | 2 | 2018 | 147 | 0.130 |
Why?
| | Vena Cava Filters | 1 | 2017 | 61 | 0.130 |
Why?
| | Pregnancy, Abdominal | 1 | 2016 | 2 | 0.130 |
Why?
| | Thromboembolism | 1 | 2017 | 119 | 0.130 |
Why?
| | Radiology Information Systems | 1 | 2016 | 30 | 0.130 |
Why?
| | Biotechnology | 1 | 2016 | 42 | 0.130 |
Why?
| | Teaching | 1 | 2018 | 224 | 0.130 |
Why?
| | Tuberous Sclerosis | 1 | 2016 | 55 | 0.120 |
Why?
| | Laboratories | 1 | 2017 | 113 | 0.120 |
Why?
| | Organizational Innovation | 1 | 2016 | 140 | 0.120 |
Why?
| | Hypertension, Portal | 1 | 2016 | 64 | 0.120 |
Why?
| | Prosthesis Design | 1 | 2017 | 327 | 0.120 |
Why?
| | Venous Thrombosis | 1 | 2017 | 190 | 0.120 |
Why?
| | Venous Insufficiency | 1 | 2015 | 12 | 0.120 |
Why?
| | Cavernous Sinus | 1 | 2015 | 19 | 0.120 |
Why?
| | Radiography, Interventional | 1 | 2016 | 116 | 0.120 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 226 | 0.110 |
Why?
| | Methotrexate | 1 | 2016 | 260 | 0.110 |
Why?
| | Arteriovenous Fistula | 1 | 2015 | 36 | 0.110 |
Why?
| | Personal Satisfaction | 1 | 2017 | 207 | 0.110 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2015 | 50 | 0.110 |
Why?
| | Portal Vein | 1 | 2016 | 120 | 0.110 |
Why?
| | Radiology Department, Hospital | 1 | 2014 | 16 | 0.110 |
Why?
| | Hernia, Abdominal | 1 | 2013 | 6 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 486 | 0.110 |
Why?
| | Ascites | 1 | 2013 | 46 | 0.100 |
Why?
| | Hernia, Inguinal | 1 | 2013 | 36 | 0.100 |
Why?
| | Intestinal Obstruction | 1 | 2013 | 51 | 0.100 |
Why?
| | Embolization, Therapeutic | 1 | 2015 | 229 | 0.100 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2013 | 91 | 0.100 |
Why?
| | Cholangiocarcinoma | 1 | 2013 | 104 | 0.090 |
Why?
| | Translocation, Genetic | 1 | 2012 | 105 | 0.090 |
Why?
| | Radiography | 1 | 2013 | 822 | 0.090 |
Why?
| | Education, Medical | 1 | 2014 | 266 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2016 | 10811 | 0.080 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 122 | 0.080 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2012 | 234 | 0.080 |
Why?
| | Disease Progression | 3 | 2013 | 2757 | 0.080 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2010 | 57 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2012 | 801 | 0.080 |
Why?
| | Carcinoma, Papillary | 1 | 2009 | 81 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 951 | 0.080 |
Why?
| | Piperazines | 1 | 2011 | 350 | 0.080 |
Why?
| | Neuroblastoma | 1 | 2010 | 160 | 0.070 |
Why?
| | Pyrazoles | 1 | 2012 | 423 | 0.070 |
Why?
| | Pyridines | 1 | 2012 | 506 | 0.070 |
Why?
| | Pyrimidines | 1 | 2011 | 470 | 0.070 |
Why?
| | Lung Neoplasms | 2 | 2012 | 2526 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2013 | 786 | 0.070 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2009 | 252 | 0.060 |
Why?
| | DNA Methylation | 1 | 2011 | 643 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2012 | 916 | 0.060 |
Why?
| | Anatomic Landmarks | 2 | 2016 | 29 | 0.060 |
Why?
| | United States | 4 | 2018 | 14841 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 5778 | 0.060 |
Why?
| | Aged | 5 | 2016 | 23961 | 0.050 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1081 | 0.050 |
Why?
| | Humans | 15 | 2018 | 137585 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 4 | 2016 | 2691 | 0.050 |
Why?
| | Young Adult | 4 | 2016 | 13209 | 0.040 |
Why?
| | Male | 6 | 2016 | 67762 | 0.040 |
Why?
| | Incidence | 2 | 2016 | 2804 | 0.040 |
Why?
| | Intergenerational Relations | 1 | 2017 | 23 | 0.030 |
Why?
| | Forecasting | 1 | 2018 | 389 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2011 | 1389 | 0.030 |
Why?
| | Hemoperitoneum | 1 | 2016 | 12 | 0.030 |
Why?
| | Inventions | 1 | 2016 | 20 | 0.030 |
Why?
| | Device Removal | 1 | 2017 | 136 | 0.030 |
Why?
| | Career Choice | 1 | 2018 | 219 | 0.030 |
Why?
| | Portography | 1 | 2016 | 12 | 0.030 |
Why?
| | Portal Pressure | 1 | 2016 | 4 | 0.030 |
Why?
| | History, 20th Century | 1 | 2017 | 325 | 0.030 |
Why?
| | Pregnancy, Ectopic | 1 | 2016 | 53 | 0.030 |
Why?
| | Female | 8 | 2016 | 73304 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2016 | 129 | 0.030 |
Why?
| | Delayed Diagnosis | 1 | 2016 | 91 | 0.030 |
Why?
| | Radiation Exposure | 1 | 2016 | 49 | 0.030 |
Why?
| | Models, Organizational | 1 | 2016 | 151 | 0.030 |
Why?
| | Operative Time | 1 | 2016 | 145 | 0.030 |
Why?
| | Fluoroscopy | 1 | 2016 | 154 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2016 | 145 | 0.030 |
Why?
| | Program Development | 1 | 2017 | 364 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2016 | 179 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 514 | 0.030 |
Why?
| | Carbon Dioxide | 1 | 2016 | 267 | 0.030 |
Why?
| | Time Factors | 2 | 2016 | 6828 | 0.030 |
Why?
| | Adult | 5 | 2016 | 37929 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2016 | 316 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2016 | 15657 | 0.030 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 78 | 0.020 |
Why?
| | Contrast Media | 1 | 2016 | 467 | 0.020 |
Why?
| | Program Evaluation | 1 | 2017 | 898 | 0.020 |
Why?
| | Ultrasonography | 1 | 2016 | 759 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2013 | 530 | 0.020 |
Why?
| | Bile Duct Neoplasms | 1 | 2013 | 124 | 0.020 |
Why?
| | Genes, Neoplasm | 1 | 2011 | 22 | 0.020 |
Why?
| | Laparoscopy | 1 | 2016 | 466 | 0.020 |
Why?
| | Imatinib Mesylate | 1 | 2011 | 79 | 0.020 |
Why?
| | Genotype | 1 | 2016 | 1916 | 0.020 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2011 | 56 | 0.020 |
Why?
| | Adolescent | 3 | 2016 | 21513 | 0.020 |
Why?
| | Data Collection | 1 | 2014 | 673 | 0.020 |
Why?
| | Middle Aged | 4 | 2016 | 33479 | 0.020 |
Why?
| | Reoperation | 1 | 2013 | 573 | 0.020 |
Why?
| | ras Proteins | 1 | 2012 | 153 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2012 | 182 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 889 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 267 | 0.020 |
Why?
| | Benzamides | 1 | 2011 | 216 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1946 | 0.020 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2012 | 215 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 861 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 767 | 0.020 |
Why?
| | Risk Factors | 2 | 2013 | 10388 | 0.020 |
Why?
| | Nephrectomy | 1 | 2010 | 169 | 0.020 |
Why?
| | Genome, Human | 1 | 2011 | 425 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 658 | 0.020 |
Why?
| | Kidney | 1 | 2016 | 1468 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 614 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1704 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2012 | 648 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2011 | 812 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 294 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1325 | 0.020 |
Why?
| | Cisplatin | 1 | 2009 | 320 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1509 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 3284 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1570 | 0.020 |
Why?
| | Cell Line | 1 | 2012 | 2847 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2016 | 6079 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3412 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4565 | 0.010 |
Why?
| | Pregnancy | 1 | 2016 | 6763 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 1079 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 7635 | 0.010 |
Why?
| | Infant | 1 | 2016 | 9465 | 0.010 |
Why?
| | Child, Preschool | 1 | 2016 | 11074 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 4030 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1692 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 3958 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 2129 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3566 | 0.010 |
Why?
| | Child | 1 | 2016 | 21935 | 0.010 |
Why?
|
|
Kondo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|